Zobrazeno 1 - 10
of 174
pro vyhledávání: '"Mišo, Šabovič"'
Autor:
Senta Frol, Janja Pretnar Oblak, Pawel Kermer, George Ntaios, Panagiotis Papanagiotou, Mišo Šabovič
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/cb8366f2b2bb4c7292366b5c1d9d6958
Autor:
Senta Frol MD, PhD, Janja Pretnar Oblak MD, PhD, Mišo Šabovič MD, PhD, Wim H. van Zwam MD, PhD, George Ntaios MD, PhD, Karl Olof Lövblad MD, PhD, Andreas Gruber MD, PhD, Pawel Kermer MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 30 (2024)
Direct oral anticoagulants (DOACs) changed stroke prevention and decreased the risk of ischemic and hemorrhagic complications in patients on oral anticoagulation (OAC) therapy. The numbers of patients prescribed DOACs has increased rapidly. Availabil
Externí odkaz:
https://doaj.org/article/b6e40899c77746c597e1912d478667e3
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients suffering from life-threatening or uncontrolled bleeding and those in
Externí odkaz:
https://doaj.org/article/c87830a1c8eb437887d83241832df3a5
Publikováno v:
Neurology International, Vol 15, Iss 3, Pp 1191-1199 (2023)
Immune thrombocytopenia (ITP) is an autoimmune blood disorder characterised by isolated severe thrombocytopenia. Arterial thrombotic events, such as acute ischaemic stroke (AIS), are rare complications. A 56-year-old woman with chronic ITP on eltromb
Externí odkaz:
https://doaj.org/article/73c78000620d4c3989bb2e8d7ff1733a
Autor:
Martina Turk Veselič, Mišo Šabovič
Publikováno v:
Zdravniški Vestnik, Vol 91, Iss 3-4, Pp 128-140 (2022)
Cilj sekundarne preventive po srčnem infarktu je zmanjšati tveganje za ponovne srčno-žilne dogodke, druge zaplete in umrljivost. Kljub medikamentni terapiji, ki so jo skozi čas priporočale smernice, je vedno ostajalo in še ostaja prisotno dolo
Externí odkaz:
https://doaj.org/article/e97f13b9bd3641ea807da83a9b232b16
Autor:
Miodrag Janić, Matej Cankar, Jan Šmid, Alenka France Štiglic, Aleš Jerin, Mišo Šabovič, Andrej Janež, Mojca Lunder
Publikováno v:
Journal of Diabetes Research, Vol 2022 (2022)
Background and Aim. Our previous study showed that the empagliflozin-metformin combination significantly improved arterial function; i.e., it improved endothelial function (measured by flow-mediated dilation and reactive hyperaemia index) and reduced
Externí odkaz:
https://doaj.org/article/b6692347865d441b932ffd15faa74510
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigat
Externí odkaz:
https://doaj.org/article/fee5726ca7584226ac90e79af65ec1fa
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Background and Purpose: Idarucizumab achieves instant reversal of anticoagulation and enables intravenous thrombolysis (IVT) in dabigatran-treated acute ischemic stroke (AIS) patients. AIS in dabigatran-treated patients is a rare event, therefore the
Externí odkaz:
https://doaj.org/article/1c6ec7c293254c5d8b01034aeef1aff7
Publikováno v:
Journal of Thrombosis and Thrombolysis. 55:506-518
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb29a65052c4900d87fcd87ba44809eb
https://doi.org/10.1007/s11239-023-02772-3
https://doi.org/10.1007/s11239-023-02772-3
Publikováno v:
CNS Drugs. 37:133-141
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c19eb032ea72af455f171419e3d790c
https://doi.org/10.1007/s40263-022-00981-7
https://doi.org/10.1007/s40263-022-00981-7